Recall Record

Buena, NJ, United States

Teligent Pharma, Inc. recalls

19 recalls recorded since 2018, most recently on 15 March 2022. 4 are listed as ongoing. Status and classification are as published by the FDA.

Recalls19
Ongoing (FDA)4
Terminated or completed15
Class I (FDA)3

Terminated Class II Drugs

Recall started
15 March 2022
Terminated
17 June 2024
Reason
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-0696-2022, D-0678-2022, D-0697-2022, D-0705-2022, D-0675-2022, D-0694-2022, D-0687-2022, D-0699-2022, D-0688-2022, D-0670-2022, D-0703-2022, D-0686-2022 and 25 more

Terminated Class II Drugs

Recall started
7 February 2022
Terminated
9 May 2024
Reason
Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
Distribution
Nationwide in the USA.
Initiated
Voluntary: Firm initiated
Recall number
D-0716-2022

Ongoing Class I, Class II Drugs

Recall started
30 November 2021
Reason
Superpotent Drug: Minimally superpotent
Distribution
Distributed to a wholesaler in CO who further distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0296-2022, D-0295-2022

Terminated Class II Drugs

Recall started
19 October 2021
Terminated
18 June 2024
Reason
Defective Container
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall numbers
D-0259-2022, D-0258-2022

Terminated Class I, Class II Drugs

Recall started
12 October 2021
Terminated
18 June 2024
Reason
Superpotent Drug
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall numbers
D-0280-2022, D-0281-2022, D-0279-2022

Terminated Class II Drugs

Recall started
23 August 2021
Terminated
16 August 2024
Reason
Failed Stability Specifications: lot did not meet specification for the Active Pharmaceutical Ingredient (API) particle test, which was determined through routine stability testing
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0297-2022

Ongoing Class I Drugs

Recall started
3 August 2021
Reason
Superpotent Drug
Distribution
Nationwide within the United States and Canada
Initiated
Voluntary: Firm initiated
Recall number
D-0800-2021

Terminated Class III Drugs

Recall started
29 July 2021
Terminated
15 August 2024
Reason
Failed Viscosity Specifications: lot does not meet specification for Viscosity, which was determined through routine testing.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0785-2021

Ongoing Class II Drugs

Recall started
29 July 2021
Reason
Defective container: possibility for lack of seal integrity.
Distribution
USA Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0769-2021

Terminated Class II Drugs

Recall started
19 July 2021
Terminated
16 August 2024
Reason
Correct Labeled Product Mispack
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-0752-2021, D-0751-2021

Terminated Class III Drugs

Recall started
22 June 2021
Terminated
3 July 2024
Reason
Failed Impurities/Degradation Specifications
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-0690-2021, D-0689-2021

Terminated Class II Drugs

Recall started
14 May 2021
Terminated
22 August 2022
Reason
Presence of Foreign Substance: Foreign particles observed during routine stability testing.
Distribution
Nationwide in the United States
Initiated
Voluntary: Firm initiated
Recall number
D-0636-2021

Ongoing Class II Drugs

Recall started
9 April 2021
Reason
Failed Impurities/Degradation Specifications:
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0356-2021

Terminated Class III Drugs

Recall started
29 March 2021
Terminated
3 July 2024
Reason
Failed Stability Specifications: product did not meet viscosity results.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0331-2021

Terminated Class III Drugs

Recall started
2 February 2021
Terminated
15 August 2024
Reason
Failed Impurities/ Degradation Specifications - OOS for know impurity Betamethasone 17- propionate.
Distribution
USA Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-0338-2021, D-0340-2021, D-0339-2021

Terminated Class III Drugs

Recall started
5 November 2020
Terminated
16 August 2024
Reason
Superpotent and Subpotent; low and high assay results
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0119-2021

Terminated Class III Drugs

Recall started
3 November 2020
Terminated
21 December 2023
Reason
Subpotent Drug: One lot of Triamcinolone Acetonide Lotion, 0.025% 60 mL.does not meet assay results.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0110-2021

Terminated Class III Drugs

Recall started
28 September 2020
Terminated
22 August 2022
Reason
Failed Impurities/Degradation - Out-of-specification results for Fluocinolone Acetonide impurity.
Distribution
United States Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0064-2021

Terminated Class III Drugs

Recall started
20 May 2019
Terminated
27 January 2025
Reason
Failed Impurities/Degradation Specifications
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-1391-2019

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.